| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/S0167-5699(00)01718-7 |
| P698 | PubMed publication ID | 11071528 |
| P50 | author | Josef Penninger | Q1674391 |
| P2093 | author name string | Y Y Kong | |
| W J Boyle | |||
| P2860 | cites work | TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo | Q36375923 |
| Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease | Q36375982 | ||
| In vivo detection of dendritic cell antigen presentation to CD4(+) T cells. | Q36377341 | ||
| TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor | Q36380989 | ||
| RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism | Q37108966 | ||
| Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin | Q39116155 | ||
| The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. | Q41649459 | ||
| A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1beta, TNF-alpha, PTH, PTHrP, and 1, 25(OH)2D3. | Q41687961 | ||
| Bone mineral density and bone metabolism in diabetes mellitus | Q41710701 | ||
| The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis | Q47569532 | ||
| Lymph node genesis is induced by signaling through the lymphotoxin beta receptor | Q47713223 | ||
| The lymphotoxin beta receptor controls organogenesis and affinity maturation in peripheral lymphoid tissues | Q47713235 | ||
| Selective disruption of lymphotoxin ligands reveals a novel set of mucosal lymph nodes and unique effects on lymph node cellular organization. | Q52528591 | ||
| Dendritic cells capable of stimulating T cells in germinal centres | Q60085015 | ||
| Role of lymphotoxin and the type I TNF receptor in the formation of germinal centers | Q71095987 | ||
| Mice deficient for the CD40 ligand | Q72610555 | ||
| Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord | Q73766127 | ||
| Developing lymph nodes collect CD4+CD3- LTbeta+ cells that can differentiate to APC, NK cells, and follicular cells but not T or B cells | Q73838320 | ||
| Bone mineral density and bone turnover in asthmatics treated with long-term inhaled or oral glucocorticoids | Q77152862 | ||
| Bone loss in autoimmune chronic active hepatitis on maintenance corticosteroid therapy | Q93615302 | ||
| Inherited human Caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II | Q22010404 | ||
| Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation | Q24311588 | ||
| Osteoprotegerin: a novel secreted protein involved in the regulation of bone density | Q24313918 | ||
| TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells | Q24315251 | ||
| A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function | Q24336057 | ||
| RANK is essential for osteoclast and lymph node development | Q24598872 | ||
| osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification | Q24603266 | ||
| Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand | Q24653311 | ||
| Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL | Q24682139 | ||
| Dendritic cells and the control of immunity | Q27860918 | ||
| Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity | Q28138855 | ||
| Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis | Q28141482 | ||
| TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src | Q28142620 | ||
| Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival | Q28142897 | ||
| RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis | Q28293009 | ||
| Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin | Q28507630 | ||
| The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation | Q28586300 | ||
| Abnormal development of secondary lymphoid tissues in lymphotoxin beta-deficient mice | Q28587099 | ||
| Distinct roles in lymphoid organogenesis for lymphotoxins alpha and beta revealed in lymphotoxin beta-deficient mice | Q28587819 | ||
| OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis | Q28589430 | ||
| Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand | Q29619331 | ||
| Role of cytokines in rheumatoid arthritis | Q29620713 | ||
| Enhanced prostanoid release from monocytes of patients with rheumatoid arthritis and active systemic lupus erythematosus | Q33555976 | ||
| Selection of the T cell repertoire. | Q33652536 | ||
| Cell biology of the osteoclast | Q33700885 | ||
| Development of peripheral lymphoid organs and natural killer cells depends on the helix-loop-helix inhibitor Id2. | Q33854381 | ||
| Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. | Q34469691 | ||
| Peyer's patch organogenesis is intact yet formation of B lymphocyte follicles is defective in peripheral lymphoid organs of mice deficient for tumor necrosis factor and its 55-kDa receptor | Q36184139 | ||
| TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation | Q36368029 | ||
| Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression | Q36368539 | ||
| Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells | Q36375909 | ||
| CD40-independent pathways of T cell help for priming of CD8(+) cytotoxic T lymphocytes | Q36375919 | ||
| P433 | issue | 10 | |
| P921 | main subject | physiology | Q521 |
| P304 | page(s) | 495-502 | |
| P577 | publication date | 2000-10-01 | |
| P1433 | published in | Trends in Immunology | Q15265730 |
| P1476 | title | Osteoprotegerin ligand: a regulator of immune responses and bone physiology | |
| P478 | volume | 21 |
| Q47868183 | -643C > T RANKL gene polymorphism is associated with osteoporosis in Tunisian postmenopausal women |
| Q37671291 | Andrographolide suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo. |
| Q34718143 | Apoptosis as a therapeutic tool in rheumatoid arthritis |
| Q35229853 | Bone density and hyperlipidemia: the T-lymphocyte connection |
| Q50079075 | Cardiovascular Autonomic Dysfunction: Link Between Multiple Sclerosis Osteoporosis and Neurodegeneration. |
| Q40143945 | Cytokine-induced osteoprotegerin expression protects pancreatic beta cells through p38 mitogen-activated protein kinase signalling against cell death |
| Q35064380 | Death receptors and their role in dermatology, with particular focus on tumor necrosis factor-related apoptosis-inducing ligand receptors |
| Q34264032 | Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines |
| Q40706650 | Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland |
| Q35155045 | Development of a novel surrogate virus for human T-cell leukemia virus type 1: inhibition of infection by osteoprotegerin. |
| Q37293002 | Diabetes and osteoporosis. |
| Q47968062 | Discovery of distinctive gene expression profiles in rheumatoid synovium using cDNA microarray technology: evidence for the existence of multiple pathways of tissue destruction and repair |
| Q81356317 | Early effects of tocilizumab on bone and bone marrow lesions in a collagen-induced arthritis monkey model |
| Q47275632 | Effect of unfractionated and low-molecular-weight heparin on OPG, sRANKL, and von Willebrand factor concentrations during hemodialysis |
| Q38732579 | Efficacy of stem cells on periodontal regeneration: Systematic review of pre-clinical studies. |
| Q35772272 | Expression of bone-regulatory proteins in human valve allografts |
| Q35606790 | Extracellular and intracellular decoys in the tuning of inflammatory cytokines and Toll-like receptors: the new entry TIR8/SIGIRR. |
| Q34429634 | Extraintestinal manifestations of inflammatory bowel disease |
| Q36410243 | Glucagon-like peptide-1(GLP-1) receptor agonists: potential to reduce fracture risk in diabetic patients? |
| Q37777482 | HIV and bone disease |
| Q40810326 | IL-1- and TNF-induced bone resorption is mediated by p38 mitogen activated protein kinase |
| Q53612779 | Identification of the osteoprotegerin/receptor activator of nuclear factor-kappa B ligand system in gingival crevicular fluid and tissue of patients with chronic periodontitis. |
| Q92967226 | Impact of periodontal treatment on the RANKL/OPG ratio in crevicular fluid |
| Q34415078 | Inflammatory and bone turnover markers in relation to PTH and vitamin D status among Saudi postmenopausal women with and without osteoporosis |
| Q86044467 | Inflammatory and bone turnover markers in relation to PTH and vitamin D status among saudi postmenopausal women with and without osteoporosis |
| Q36565219 | Inflammatory bowel diseases as secondary causes of osteoporosis |
| Q59083003 | Interfering with bone remodelling |
| Q50987004 | Internal prostaglandin synthesis augments osteoprotegerin production in human gingival fibroblasts stimulated by lipopolysaccharide. |
| Q53955124 | LPS-stimulated human gingival fibroblasts inhibit the differentiation of monocytes into osteoclasts through the production of osteoprotegerin. |
| Q37780487 | Levels of osteoprotegerin (OPG) and receptor activator for nuclear factor kappa B ligand (RANKL) in serum: are they of any help? |
| Q40538587 | Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblast pathway of osteoclast stimulation. |
| Q28542802 | Olmesartan decreased levels of IL-1β and TNF-α, down-regulated MMP-2, MMP-9, COX-2, RANK/RANKL and up-regulated SOCs-1 in an intestinal mucositis model |
| Q39946675 | Osteolysis and cancer |
| Q97530990 | Osteoporotic fracture rates in chronic hemodialysis and effect of heparin exposure: a retrospective cohort study |
| Q39445928 | Pathogenesis of Metastatic Calcification and Acute Pancreatitis in Adult T-Cell Leukemia under Hypercalcemic State. |
| Q38211488 | Pharmacology of intra-articular triamcinolone |
| Q38112453 | Phytoestrogens and bone health at different reproductive stages. |
| Q34828137 | Plasma and drainage fluid levels of soluble receptor activator of nuclear factor-kB (sRANK), soluble receptor activator of nuclear factor-kB ligand (sRANKL) and osteoprotegerin (OPG) during proximal humerus fracture healing |
| Q43984049 | Platelet-released supernatants stimulate formation of osteoclast-like cells through a prostaglandin/RANKL-dependent mechanism |
| Q37307876 | Prevention of bone mineral density loss in patients with rheumatoid arthritis treated with anti-TNFalpha therapy. |
| Q37199218 | RANK, RANKL and osteoprotegerin in bone biology and disease. |
| Q48182386 | RANKL/RANK/OPG cytokine receptor system: mRNA expression pattern in BPH, primary and metastatic prostate cancer disease |
| Q44552390 | Receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin levels in multiple sclerosis |
| Q53188305 | Receptor activator of nuclear factor-κB ligand is a novel inducer of myocardial inflammation. |
| Q42852092 | Relationship between RANKL and neuroendocrine activation in elderly males with heart failure |
| Q52620654 | Resolvin E1 Inhibits Osteoclastogenesis and Bone Resorption by Suppressing IL-17-induced RANKL Expression in Osteoblasts and RANKL-induced Osteoclast Differentiation. |
| Q35792875 | Risk of low bone mineral density in patients with rheumatoid arthritis treated with biologics |
| Q35165886 | Role of RANKL-RANK/osteoprotegerin molecular complex in bone remodeling and its immunopathologic implications |
| Q40762664 | Role of TGF-beta family in osteoclastogenesis induced by RANKL. |
| Q44192941 | Serum osteoprotegerin is increased in Crohn's disease: a population-based case control study |
| Q36847530 | Structural simulation of adenosine phosphate via plumbagin and zoledronic acid competitively targets JNK/Erk to synergistically attenuate osteoclastogenesis in a breast cancer model |
| Q41684447 | The Beneficial Effect of Praeruptorin C on Osteoporotic Bone in Ovariectomized Mice via Suppression of Osteoclast Formation and Bone Resorption |
| Q39061470 | The Effect of Orthognathic Surgery on Osteoprotegerin as Immunological Caliper of Bone Healing |
| Q47167957 | The Effect of RANKL/OPG Balance on Reducing Implant Complications |
| Q46212623 | The osteoprotegerin/receptor activator of nuclear factor kappaB/receptor activator of nuclear factor kappaB ligand system in cartilage |
| Q36121037 | The role of CD8+ T-cell replicative senescence in human aging |
| Q35246409 | The role of polyunsaturated ω-3 fatty acid eicosapentaenoic acid-derived resolvin E1 (RvE1) in bone preservation |